October 2019

Partnering – November 2019

BIO-Europe 2019
Interested to hear more about Cellestia's latest news? Join our COO, Dr. Maximilien Murone, at BIO-Europe (November 11–13, 2019), in Hamburg.

October 2019

Science – October 2019

The NOTCH Meeting XI
Meet our COO, Dr. Maximilien Murone, at The NOTCH Meeting XI (October 6-10, 2019) in Athens. Key experts in the field of NOTCH research will be covering the breadth of science related to this topic.

2nd European Oncology and Immuno-Oncology Drug Discovery Symposium
Join us at the at Champions Oncology drug discovery symposium (October 22, 2019) in Basel. Our CSO, Dr Raj Lehal, will be giving a presentation that day (Discovery and development of a first-in-class protein-protein interaction inhibitor targeting the NOTCH pathway).

StartLab at Biopole Lausanne
Cellestia Biotech joined at StartLab at Biopole Lausanne in September 2019. Our R&D Lab is now fully operational.

September 2019

Partnering – September 2019

Biopharm America
Join us and meet our CFO Gaudenz von Capeller at Biopharm America, part of the Biotech week (September 11–12, 2019) in Boston.

19th Annual Biotech in Europe Forum (SACHS)
Join Cellestia’s team at the 19th Annual Biotech in Europe Forum (September 25–26, 2019) in Basel. Our CFO (Gaudenz von Capeller), COO (Maximilien Murone) and Head of Communication (Mathilde Claire Vincent) will be pleased to meet you.

September 2019

Science – September 2019

Convergence in Oncology Summit
Our COO Maximilien Murone will be attending the Convergence in Oncology Summit at Biopôle (September 12–13, 2019) in Lausanne. The Convergence in Oncology Summit is an international annual assembly of industry leaders, entrepreneurs, and investors active in the field of Oncology to debate and explore synergies that can accelerate the development of the most promising solutions in the field.

European Society for Medical Oncology (ESMO) Congress
Meet Dr. Pavel Pisa, our Medical Director at ESMO Congress (September 27–October 1, 2019) in Barcelona.
ESMO 2019 will be the global stage for excellence in translational research, presentation of practice-changing data and multidisciplinary discussions.

Cancer Care 2019
Our CSO Rajwinder Lehal will give a presentation about Targeting undruggable oncogenic transcription factors, at Cancer Care (September 20, 2019, at 10 am) in Bern.
Join and meet him !

July 2019

Board of Directors

Guido Guidi and Robert Karsunky have been elected to Cellestia’s Board of Directors. Guido Guidi is the new Chairman of the Board.

June 2019

9th International Conference – NOTCH Targeting in Cancer

Meet our CSO Rajwinder Lehal and attend the following sessions, at Grecian Park Hotel, Konnos Bay, Cyprus (June 26–28, 2019).

On 28th June, he will be chairing the Notch Therapeutics workshop together with Lucio Miele. He will also be giving a talk in Session 7 (Novel Therapeutics) at 4.30pm on Direct targeting of NOTCH Transcription Complex by a novel small molecule CB-103 circumvents dose limiting toxicities associated with pan-NOTCH inhibitors.

May 2019

Partnering Meeting Bio€quity Europe

Meet the Cellestia team at the Bio€quity Europe meeting (May 20-21, 2019) in Barcelona.

March 2019

American Association for Cancer Research Meeting

Cellestia selected for an oral presentation on CB-103 by Dr. Raj Lehal, Chief Scientific Officer, at the Preclinical Drug Development session of the American Association for Cancer Research Meeting (Atlanta, March 29–April 3).

February 2019

IND accepted by the FDA

On Feb. 4th, Cellestia received the green light from the FDA for its Investigational New Drug Application (IND). The FDA completed its review, and concluded that Cellestia can proceed with its clinical investigation of CB-103 in tumors driven by an oncogenic NOTCH signaling pathway.

December 2018

Cellestia Biotech AG secures CHF 20 million in Series A funding

Cellestia announced today the close of a CHF 20 million Series A financing round. The financing will accelerate Cellestia’s ongoing clinical program, and advance its innovative R&D pipeline.
To read Cellestia’s press release click here.